Christophe Moreno
Université libre de Bruxelles
281 Papers
1.9K Citations
Christophe Moreno is an academic researcher from Université libre de Bruxelles. The author has contributed to research in topics: Medicine & Hepatitis C. The author has an hindex of 53, co-authored 259 publications. Previous affiliations of Christophe Moreno include Free University of Brussels & University of Toronto.
Chat about Author
Papers
A randomized, controlled study of peginterferon lambda-1a/ribavirin +/- daclatasvir for hepatitis C virus genotype 2 or 3
Graham R. Foster,Kazuaki Chayama,Wan-Long Chuang,Hugo Fainboim,Martti Färkkilä,Adrián Gadano,Giovanni Battista Gaeta,Christophe Hézode,Yukiko Inada,Jeong Heo,Hiromitsu Kumada,Sheng-Nan Lu,Patrick Marcellin,Christophe Moreno,Stuart K. Roberts,Simone I. Strasser,Alexander J. Thompson,Joji Toyota,Seung Woon Paik,John M. Vierling,Anna Linda Zignego,David Cohen,Fiona McPhee,Megan Wind-Rotolo,Subasree Srinivasan,Matthew Hruska,Heather Myler,Simon Portsmouth +27 more
TL;DR: The 12-week regimen of Lambda/RBV + DCV was superior to peginterferon alfa-2a plus RBV in the combined population of treatment-naive patients with genotype 2 or 3 infection, with an improved tolerability and safety profile compared with alfa/ RBV.
Ethical considerations regarding early liver transplantation in patients with severe alcoholic hepatitis not responding to medical therapy.
TL;DR: In this pilot experience, stringent patient selection resulted in major improvement of short-term survival with low rates of post-transplant alcohol relapse, and there are no major ethical barriers for further evaluation of this new therapeutic option.
Stopping nucleos(t)ide analogue treatment in Caucasian hepatitis B patients after HBeAg seroconversion is associated with high relapse rates and fatal outcomes.
S Van Hees,Suzanne Bourgeois,H. Van Vlierberghe,Thomas Sersté,Sven Francque,P.P. Michielsen,D. Sprengers,Hendrik Reynaert,Jean Henrion,S Negrin Dastis,J. Delwaide,L Lasser,J Decaestecker,Hans Orlent,F Janssens,G. Robaeys,Isabelle Colle,Peter Stärkel,Christophe Moreno,Frederik Nevens,Thomas Vanwolleghem +20 more
TL;DR: Stopping nucleos(t)ide analogues after hepatitis B e antigen (HBeAg) seroconversion is associated with high relapse rates in Asian patients, but data in Caucasian cohorts are scarce.
Association between the PNPLA3 (rs738409 C>G) variant and hepatocellular carcinoma: Evidence from a meta‐analysis of individual participant data
Eric Trepo,Pierre Nahon,Pierre Nahon,Gianluca Bontempi,Luca Valenti,Edmondo Falleti,Hans Dieter Nischalke,Samia Hamza,Stefano Ginanni Corradini,Maria Antonella Burza,Erwan Guyot,Benedetta Donati,Ulrich Spengler,Patrick Hillon,Pierluigi Toniutto,Jean Henrion,Denis Franchimont,Jacques Devière,Philippe Mathurin,Christophe Moreno,Stefano Romeo,Stefano Romeo,Pierre Deltenre,Pierre Deltenre +23 more
TL;DR: The results suggest that rs738409 exerts a marked influence on hepatocarcinogenesis in patients with cirrhosis of European descent and provide a strong argument for performing further mechanistic studies to better understand the role of PNPLA3 in HCC development.
ABT-450/r–Ombitasvir and Dasabuvir with or without Ribavirin for HCV
Peter Ferenci,David E. Bernstein,Jacob Lalezari,Daniel E. Cohen,Yan Luo,Curtis Cooper,Edward Tam,Rui Tato Marinho,Naoky Tsai,A. Nyberg,Terry Box,Ziad Younes,Pedram Enayati,Sinikka Green,Yaacov Baruch,Bal R. Bhandari,Florin Alexandru Caruntu,Thomas Sepe,Vladimir Chulanov,Ewa Janczewska,Giuliano Rizzardini,J. Gervain,Ramon Planas,Christophe Moreno,Tarek Hassanein,Wangang Xie,M. King,Thomas Podsadecki,K. Rajender Reddy +28 more
TL;DR: Twelve weeks of treatment with ABT-450/r-ombitasvir and dasabuvir without ribavirin was associated with high rates of sustained virologic response among previously untreated patients with HCV genotype 1 infection.